$609 Million is the total value of MPM BioImpact LLC's 14 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 7.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Management, Inc. | $203,783,000 | -38.2% | 7,913,887 | 0.0% | 33.48% | -19.2% | |
| ITOS | Sell | iTeos Therapeutics, Inc. | $59,985,000 | -25.5% | 2,338,581 | -0.7% | 9.85% | -2.6% |
| TCRR | TCR2 Therapeutics, Inc. | $55,318,000 | -25.7% | 3,370,982 | 0.0% | 9.09% | -2.8% | |
| RPTX | Sell | Repare Therapeutics, Inc. | $52,260,000 | -17.7% | 1,676,087 | -19.0% | 8.58% | +7.6% |
| HARP | Sell | Harpoon Therapeutics, Inc. | $44,338,000 | -45.6% | 3,196,707 | -18.0% | 7.28% | -28.9% |
| HOWL | New | Werewolf Therapeutics, Inc. | $41,647,000 | – | 2,388,011 | +100.0% | 6.84% | – |
| ONCR | Oncorus, Inc. | $32,803,000 | -0.9% | 2,377,031 | 0.0% | 5.39% | +29.6% | |
| MEI Pharma, Inc. | $28,893,000 | -16.9% | 10,137,859 | 0.0% | 4.75% | +8.7% | ||
| TPTX | Turning Point Therapeutics, Inc. | $21,002,000 | -17.5% | 269,186 | 0.0% | 3.45% | +7.8% | |
| EPZM | Epizyme, Inc. | $19,375,000 | -4.6% | 2,331,534 | 0.0% | 3.18% | +24.7% | |
| GTHX | Sell | G1 Therapeutics, Inc. | $17,833,000 | -20.1% | 812,794 | -12.4% | 2.93% | +4.5% |
| MRUS | Merus N.V. | $14,768,000 | +0.9% | 700,879 | 0.0% | 2.43% | +31.8% | |
| YMAB | YmAbs Therapeutics, Inc. | $11,400,000 | +11.8% | 337,291 | 0.0% | 1.87% | +46.1% | |
| ADCT | ADC Therapeutics, Inc. | $5,309,000 | -0.2% | 218,027 | 0.0% | 0.87% | +30.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.